Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMED Amedisys	$97.89 +0.4%	$94.54	$82.15 ▼ $98.95	$3.21B	0.94	418,159 shs	410,518 shs
CHE Chemed	$546.00 -0.7%	$568.51	$512.12 ▼ $623.61	$7.99B	0.54	104,676 shs	120,431 shs
OPCH Option Care Health	$31.56 -0.9%	$32.08	$21.39 ▼ $35.53	$5.17B	0.74	1.88 million shs	2.73 million shs
SWAV Shockwave Medical	$334.75	$332.85	$157.00 ▼ $334.90	$12.57B	0.88	968,088 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMED Amedisys	0.00%	+0.68%	+3.32%	+5.96%	+6.83%
CHE Chemed	0.00%	-2.15%	-5.94%	-8.14%	+2.55%
OPCH Option Care Health	0.00%	-0.97%	-4.57%	-8.73%	+13.12%
SWAV Shockwave Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMED Amedisys	3.3561 of 5 stars	1.1	3.0	0.0	5.0	2.9	1.7	1.3
CHE Chemed	4.6335 of 5 stars	2.5	3.0	3.3	4.9	2.8	2.5	1.3
OPCH Option Care Health	3.7732 of 5 stars	2.4	3.0	0.0	4.2	3.2	1.7	0.6
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMED Amedisys	2.20	Hold	$100.75	2.92% Upside
CHE Chemed	3.00	Buy	$674.00	23.44% Upside
OPCH Option Care Health	2.88	Moderate Buy	$35.50	12.48% Upside
SWAV Shockwave Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CHE, AMED, OPCH, and SWAV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$36.00
4/30/2025	OPCH Option Care Health	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$38.00 ➝ $38.00
4/30/2025	OPCH Option Care Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $40.00
4/28/2025	CHE Chemed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$667.00 ➝ $674.00
4/22/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$36.00 ➝ $36.00
4/21/2025	OPCH Option Care Health	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$38.00 ➝ $38.00
4/16/2025	AMED Amedisys	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$100.00 ➝ $100.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMED Amedisys	$2.35B	1.37	$6.23 per share	15.71	$36.03 per share	2.72
CHE Chemed	$2.43B	3.29	$25.71 per share	21.24	$74.35 per share	7.34
OPCH Option Care Health	$5.00B	1.03	$1.65 per share	19.18	$8.25 per share	3.83
SWAV Shockwave Medical	$787.97M	15.95	$4.31 per share	77.61	$20.02 per share	16.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMED Amedisys	$43.23M	$2.71	36.12	20.23	1.33	3.79%	12.52%	7.01%	7/23/2025 (Estimated)
CHE Chemed	$302M	$20.53	26.60	23.43	2.27	12.40%	27.58%	18.96%	7/23/2025 (Estimated)
OPCH Option Care Health	$211.82M	$1.24	25.45	25.05	1.91	4.12%	16.90%	7.00%	7/30/2025 (Estimated)
SWAV Shockwave Medical	$147.28M	$4.28	78.21	54.34	2.43	20.75%	24.79%	11.95%	N/A

Latest CHE, AMED, OPCH, and SWAV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	Q1 2025	OPCH Option Care Health	$0.36	$0.40	+$0.04	$0.28	$1.26 billion	$1.33 billion
4/23/2025	Q1 2025	AMED Amedisys	$1.13	$1.25	+$0.12	$1.84	$597.43 million	$594.78 million
4/23/2025	Q1 2025	CHE Chemed	$5.59	$5.63	+$0.04	$4.86	$641.78 million	$646.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMED Amedisys	N/A	N/A	N/A	N/A	N/A
CHE Chemed	$2.00	0.37%	N/A	9.74%	16 Years
OPCH Option Care Health	N/A	N/A	N/A	N/A	N/A
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A

Latest CHE, AMED, OPCH, and SWAV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	CHE Chemed	quarterly	$0.50	0.3%	5/29/2025	5/29/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMED Amedisys	0.27	1.29	1.29
CHE Chemed	N/A	1.73	1.70
OPCH Option Care Health	0.82	1.54	1.02
SWAV Shockwave Medical	0.97	13.81	12.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMED Amedisys	94.36%
CHE Chemed	95.85%
OPCH Option Care Health	98.05%
SWAV Shockwave Medical	95.35%

Insider Ownership

Company	Insider Ownership
AMED Amedisys	2.10%
CHE Chemed	3.29%
OPCH Option Care Health	0.64%
SWAV Shockwave Medical	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMED Amedisys	19,000	32.82 million	32.13 million	Optionable
CHE Chemed	15,695	14.63 million	14.15 million	Optionable
OPCH Option Care Health	8,088	163.75 million	162.70 million	Optionable
SWAV Shockwave Medical	1,468	37.54 million	36.27 million	Optionable

CHE, AMED, OPCH, and SWAV Headlines

Recent News About These Companies

Shockwave Medical unveil Forward Intravascular Lithotripsy Platform in US

March 6, 2025 | medicaldialogues.in

Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

March 4, 2025 | finance.yahoo.com

Shockwave Medical’s Javelin IVL catheter meets primary trial endpoints

November 5, 2024 | massdevice.com

Shockwave Medical concludes enrollment in all-female coronary IVL study

November 2, 2024 | medicaldialogues.in

Shockwave completes enrollment in all-female cardiovascular trial

October 30, 2024 | bioworld.com

Shockwave Medical completes enrollment in all-female IVL study

October 29, 2024 | massdevice.com

Micro-shockwave electronic therapy shows potential for safe non-invasive treatment of brain disorders

October 28, 2024 | medicalxpress.com

Mayo Clinic Q&A: Shockwave therapy may help relieve foot problem

October 27, 2024 | postbulletin.com

Johnson & Johnson completes $1.7B V-Wave acquisition

October 9, 2024 | massdevice.com

New shockwave therapy offers hope for chronic pain sufferers

September 25, 2024 | local12.com

Shockwave E8: Extend Your Capabilities With the New Peripheral IVL Workhorse

September 24, 2024 | evtoday.com

Shockwave E8 Peripheral IVL Catheter Launched

September 17, 2024 | evtoday.com

Smiths Medical recalls airway tubes over defect linked to more than 10 injuries

September 17, 2024 | medtechdive.com

J&J’s Shockwave adds enhanced catheter to U.S. IVL portfolio

September 17, 2024 | massdevice.com

J&J’s Shockwave strengths IVL grasp with new US catheter launch

September 17, 2024 | msn.com

New noninvasive technique provides effective treatment for urinary stones

September 12, 2024 | msn.com

Balancing Growth and Challenges: A Hold Rating for Johnson & Johnson’s Medtech Division Amidst China Headwinds

September 6, 2024 | markets.businessinsider.com

September 2024 edition: The Medtech Big 100, PFA catheters and Shockwave’s Reducer

August 30, 2024 | medicaldesignandoutsourcing.com

Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

August 22, 2024 | seekingalpha.com

Introducing OMNIWave(TM): Revolutionizing Treatment with Advanced Shockwave Technology and Comprehensive Business Solutions

August 15, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Penny Stocks Analysts Believe Are Headed Higher
By Chris Markoch | June 4, 2025
View 3 Penny Stocks Analysts Believe Are Headed Higher
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Government Mandate Sends eVTOL Stocks Flying
By Jeffrey Neal Johnson | June 10, 2025
View Government Mandate Sends eVTOL Stocks Flying
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
By Sarah Horvath | June 9, 2025
View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally

CHE, AMED, OPCH, and SWAV Company Descriptions

Amedisys NASDAQ:AMED

$97.89 +0.38 (+0.39%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$97.83 -0.06 (-0.07%)

As of 06/18/2025 05:07 PM Eastern

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Chemed NYSE:CHE

$546.00 -3.65 (-0.66%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$546.36 +0.37 (+0.07%)

As of 06/18/2025 04:39 PM Eastern

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Option Care Health NASDAQ:OPCH

$31.56 -0.28 (-0.88%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$31.56 0.00 (0.00%)

As of 06/18/2025 04:39 PM Eastern

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time